Co-Authors
This is a "connection" page, showing publications co-authored by JAFFER A AJANI and GORDON B MILLS.
Connection Strength
0.411
-
Dual inhibition of tumor energy pathway by 2-deoxyglucose and metformin is effective against a broad spectrum of preclinical cancer models. Mol Cancer Ther. 2011 Dec; 10(12):2350-62.
Score: 0.100
-
Phase II study of talazoparib in advanced cancers with BRCA1/2, DNA repair, and PTEN alterations. NPJ Precis Oncol. 2024 Jul 31; 8(1):166.
Score: 0.061
-
Inhibition of the ATM/Chk2 axis promotes cGAS/STING signaling in ARID1A-deficient tumors. J Clin Invest. 2020 11 02; 130(11):5951-5966.
Score: 0.047
-
Genetic alterations and expression characteristics of ARID1A impact tumor immune contexture and survival in early-onset gastric cancer. Am J Cancer Res. 2020; 10(11):3947-3972.
Score: 0.047
-
The DNA Endonuclease Mus81 Regulates ZEB1 Expression and Serves as a Target of BET4 Inhibitors in Gastric Cancer. Mol Cancer Ther. 2019 08; 18(8):1439-1450.
Score: 0.042
-
ARID1A deficiency promotes mutability and potentiates therapeutic antitumor immunity unleashed by immune checkpoint blockade. Nat Med. 2018 05; 24(5):556-562.
Score: 0.039
-
Clinical and genomic landscape of gastric cancer with a mesenchymal phenotype. Nat Commun. 2018 05 03; 9(1):1777.
Score: 0.039
-
Chk1 inhibition potentiates the therapeutic efficacy of PARP inhibitor BMN673 in gastric cancer. Am J Cancer Res. 2017; 7(3):473-483.
Score: 0.036